文献速递骨软组织肉瘤与黑色素瘤

晚期黑色素瘤的超进展不限于免疫治疗

Hyperprogression in advanced melanoma is not restricted to immunotherapy.
PubMed 文献 · Eur J Cancer · 2023-08-11

该研究基于法国前瞻性多中心队列MelBase的回顾性分析,采用结合实体瘤疗效评价标准、美国东部肿瘤协作组体能状态评分和乳酸脱氢酶的临床与生物学标准定义超进展疾病。结果显示抗PD1组超进展发生率为10%(98/1004),伊匹木单抗联合纳武利尤单抗组为6%(19/327),靶向治疗组为4%(31/751),化疗组为10%(40/397)。在抗PD1组中,超过3个转移部位(p=0.03)和肝转移(p<0.001)是超进展的相关危险因素。

要点

  • 抗PD1组超进展发生率为10%(98/1004),伊匹木单抗联合纳武利尤单抗组为6%(19/327)。
  • 靶向治疗组超进展发生率为4%(31/751),化疗组为10%(40/397)。
  • 抗PD1组中超进展的相关危险因素包括超过3个转移部位(p=0.03)和肝转移(p<0.001)。

核心结论

  • 该数据支持存在一个在单免疫治疗期间疾病快速恶化的亚组,该亚组可通过日常实践中可行的临床和生物学标准识别。
  • 超进展在其他治疗中也可观察到,可能是疾病自然侵袭性演变的结果,并被强效治疗所缓解。

研究设计与样本

  • 本研究为基于前瞻性队列的回顾性分析,数据提取自MelBase——一个法国前瞻性多中心成人晚期黑色素瘤队列。
  • 患者知情同意后前瞻性接受抗PD1、伊匹木单抗联合纳武利尤单抗、BRAF/MEK抑制剂或化疗,作为一线或后续治疗。
  • 超进展定义为治疗开始后3个月内,使用结合实体瘤疗效评价标准、美国东部肿瘤协作组体能状态评分和乳酸脱氢酶的临床与生物学标准。

主要发现

  • 抗PD1组超进展发生率为10%(98/1004),伊匹木单抗联合纳武利尤单抗组为6%(19/327),靶向治疗组为4%(31/751),化疗组为10%(40/397)。
  • 在抗PD1组中,超进展的相关危险因素为超过3个转移部位(p=0.03)和肝转移(p<0.001)。

关键数值与推荐

  • 超进展定义:治疗开始后3个月内,结合实体瘤疗效评价标准、美国东部肿瘤协作组体能状态评分和乳酸脱氢酶的临床与生物学标准。
  • 抗PD1组超进展发生率10%(98/1004)。
  • 伊匹木单抗联合纳武利尤单抗组超进展发生率6%(19/327)。
  • 靶向治疗组超进展发生率4%(31/751)。
  • 化疗组超进展发生率10%(40/397)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The definition of hyperprogressive disease (HPD) is controversial in the literature and has not been widely described in melanoma. The aim of this study was to determine whether the concept of HPD applies to patients treated for advanced melanoma, using a definition with a simple, reproducible criterion, and to determine whether it is possible to identify predictive factors for HPD. METHODS: This was a retrospective analysis on a prospective cohort. The data were extracted from MelBase, a French prospective, multicentre cohort of adult patients with advanced melanoma. The patients, following informed consent, were treated prospectively with anti-PD1, ipilimumab+nivolumab, BRAF/MEKi, or chemotherapy, 1st line or thereafter. HPD was defined, within 3 months following the start of the treatment, with the help of a clinical and biological criterion using Response Evaluation Criteria in Solid Tumours, Eastern Cooperative Oncology Group Performance Score, and lactate dehydrogenase. RESULTS: The occurrence of HPD in the 4 groups was as follows (numbers of patients out of the total number): anti-PD1 98/1004 (10%), ipilumumab +nivolumab 19/327 (6%), targeted therapy 31/751 (4%), and chemotherapy 40/397 (10%). In the anti programmed cell death protein 1 (APD1) group, the relevant risk factors for HPD were: more than 3 metastatic sites (p = 0.03) and liver metastasis (p < 0.001). CONCLUSION: This data, thanks to relevant clinical and biological criteria feasible in daily practice, supports the presence of a subgroup whose disease deteriorates rapidly during mono-immunotherapy. Also observed with other treatments, HPD could be the consequence of a natural and aggressive evolution of the disease, alleviated by strong-acting treatments.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Fournier M, Mortier L, Dereure O, et al. Hyperprogression in advanced melanoma is not restricted to immunotherapy. Eur J Cancer. 2023. PMID: 37690179. doi:10.1016/j.ejca.2023.113289

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。